Every material Form 8-K Haemonetics filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Haemonetics reported second-quarter fiscal 2027 revenue of $357.8 million, up 9.3%, and GAAP earnings of $1.00 per diluted share, up from $0.81 a year earlier. The company raised its reported revenue growth guidance to 8% to 11% but narrowed its adjusted operating margin expansion guidance to 0 to 50 basis points from 50 to 100 basis points.
Q2 revenue $357.8 million, up 9.3%; organic revenue growth 10.0%
GAAP EPS $1.00 vs. $0.81 a year earlier; adjusted EPS $1.35, up 6.3%
Reported revenue guidance raised to 8% to 11% from 5% to 8%; adjusted operating margin expansion lowered to 0 to 50 basis points from 50 to 100
Haemonetics reported first-quarter fiscal 2027 revenue of $339.4 million, up 5.6%, with GAAP earnings of $0.72 per diluted share versus $0.70 a year earlier. The company raised its fiscal 2027 organic revenue growth guidance to 4% to 7% from 3% to 6%, though GAAP net income fell 3.0% to $33.0 million.
Q1 fiscal 2027 revenue was $339.4 million, up 5.6%; organic revenue growth was 5.9%.
GAAP diluted EPS was $0.72 versus $0.70; adjusted diluted EPS was $1.14, up 3.6%.
Organic revenue growth guidance was raised to 4% to 7% from 3% to 6%; reported revenue guidance was raised to 5% to 8% from 4% to 7%.
Free cash flow was $39.1 million, up $36.6 million; cash on hand was $223.4 million as of June 27, 2026.
Haemonetics' board elected Martin Madaus, a Carlyle Group Senior Operating Executive, as a director effective July 24, 2026. At the same meeting, shareholders re-elected eight directors, approved an advisory say-on-pay vote, ratified Ernst & Young LLP as auditor, and approved amended 2019 Long-Term Incentive Compensation and 2007 Employee Stock Purchase Plans. The plan changes authorize 4,680,000 additional shares under the incentive plan and extend both plans through 2036.
Martin Madaus elected director effective July 24, 2026; expected to join the Audit Committee and Governance and Compliance Committee
Non-employee director annual equity award with an approximate value of $200,000
Shareholders approved the incentive plan amendment, which authorizes 4,680,000 additional shares, with 37,730,923 votes for and 2,055,726 against
Ellen Zane, Christopher Simon and six other nominees re-elected for one-year terms expiring in 2027
Haemonetics reported fourth-quarter fiscal 2026 revenue of $346.4 million, up 4.8%, and adjusted earnings of $1.29 per diluted share, up 4.0%. A $77.2 million impairment of intangible assets tied to Attune Medical turned the quarter to a GAAP net loss of $20.1 million, or $(0.44) per share, and the company also issued fiscal 2027 guidance calling for reported revenue growth of 4% to 7%.
Q4 fiscal 2026 revenue of $346.4 million, up 4.8%; organic growth 4.5%, organic ex-CSL growth 8.6%
Q4 GAAP net loss of $20.1 million, or $(0.44) per share, versus net income of $58.0 million, or $1.17 per share, a year earlier
Fiscal 2026 revenue of $1.334 billion, down 2.0%; GAAP EPS $2.05 versus $3.31; adjusted EPS $4.96
Fiscal 2027 guidance: reported revenue growth 4% to 7%, organic growth 3% to 6%, adjusted operating margin expansion of 50 to 100 basis points
Haemonetics director Charles J. Dockendorff told the company on April 27, 2026 that he will not stand for re-election at the 2026 Annual Meeting of Shareholders. He will remain a director and keep his Audit and Governance and Compliance Committee roles until that meeting, and the filing says the decision is not the result of any disagreement with the company.
Charles J. Dockendorff informed the company on April 27, 2026 of his decision
He has served on the Board since 2014 and sits on the Audit Committee and Governance and Compliance Committee
He will serve until the 2026 Annual Meeting of Shareholders
The filing states the decision is not the result of any disagreement with the company
Haemonetics reported third-quarter fiscal 2026 revenue of $339.0 million, down 2.7% from a year earlier, while GAAP net income rose 19.3% to $44.7 million. The company raised its fiscal 2026 adjusted earnings per diluted share guidance to $4.90 to $5.00 from $4.80 to $5.00 and raised its free cash flow guidance to $200 million to $220 million from $170 million to $210 million.
Q3 revenue was $339.0 million, down 2.7%; organic revenue declined 1.2%, and organic ex-CSL revenue rose 7.5%.
GAAP earnings per diluted share were $0.95, up from $0.74; adjusted earnings per diluted share were $1.31, up 10.1%.
Q3 free cash flow was $74.2 million, up 150.9%; cash on hand was $363.4 million as of December 27, 2025.
Fiscal 2026 adjusted earnings per diluted share guidance now $4.90 to $5.00; free cash flow guidance now $200 million to $220 million.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Haemonetics filing is on SEC EDGAR ↗. 8-K briefs of other companies →